Article Contents ::
- 1 The Brand Name CLOPIXOL ACUPHASE Has Generic Salt :: Zuclopenthixol
- 2 CLOPIXOL ACUPHASE Is From Company Lundbeck Priced :: Rs. 110
- 3 CLOPIXOL ACUPHASE have Zuclopenthixol is comes under Sub class #N/A of Main Class #N/A
- 4 Main Medicine Class:: #N/A Sub Medicine Class :: #N/A
- 5 Disclaimer ::
- 6 The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.
The Brand Name CLOPIXOL ACUPHASE Has Generic Salt :: Zuclopenthixol
CLOPIXOL ACUPHASE Is From Company Lundbeck Priced :: Rs. 110
CLOPIXOL ACUPHASE have Zuclopenthixol is comes under Sub class #N/A of Main Class #N/A
Main Medicine Class:: #N/A Sub Medicine Class :: #N/A
| Salt Name : OR Generic Name | Form | Price : MRP /Probable | Packing | ||
| Zuclopenthixol | INJ | Rs. 110 | 2ML |
| Brand Name | Company / Manufacturers | Strength | Unit | Price / 2ML |
| CLOPIXOL ACUPHASE | Lundbeck | 100 MG/ML | 2ML | Rs. 110 |
| Company Brand Name | Salt Combination | Main Medical Class | Sub Medical Class |
| From Lundbeck :: CLOPIXOL ACUPHASE | Zuclopenthixol | #N/A | #N/A |
Indications for Drugs ::
Schizophrenia, Psychoses, Bipolar mania
Drug Dose ::
Adult: PO Psychoses Initial: 20-30 mg/day in divided doses. Maintenance: 20-50 mg/day. Max: 150 mg/day. IM Acute psychosis As acetate ester: 150 mg, repeat if needed 2-3 days later. Max cumulative dose: 400 mg/course. Max number of inj: 4/course. Max duration: 2 wk. Chronic psychosis As decanoate ester: Initial: 100 mg as test dose, followed after at least 1 wk by 200-500 mg or more, repeated at 1-4 wkly if needed. Max: 600 mg/wk. Inj >2 mL to be distributed between 2 inj sites.
Contraindication ::
Hypersensitivity. Comatose states e.g. alcohol, barbiturate and opiate intoxications; porphyria. children.
Drug Precautions ::
Hepatic and renal impairment, heart disease, recent acute MI, arrhythmias, significant bradycardia (<50 beats/min), severe respiratory disease, epilepsy (and conditions at risk of epilepsy, e.g. alcohol withdrawal or brain damage), Parkinson's disease, acute angle glaucoma, prostatic hypertrophy, hypothyroidism, hyperthyroidism, myasthenia gravis, phaeochromocytoma. Patients at risk of stroke and QT interval prolongation. Avoid abrupt withdrawal. Ability to drive a car or operate machinery may be impaired. Drug Side Effects ::
Drowsiness, blurred vision, tachycardia, nausea, dizziness, headache, excitement, postural hypotension, hyperprolactinaemia, sexual dysfunction, ECG changes (prolongation of QT interval and T wave changes), hyperthermia. Extrapyramidal symptoms may occur, especially during the early phase of treatment; urinary frequency or incontinence; tardive dyskinesia. Potentially Fatal: Neuroleptic malignant syndrome, blood dyscrasias.
Pregnancy category ::
3
Drug Mode of Action ::
Zuclopenthixol has high affinity for D1 and D2 receptors and ?-adrenoreceptors. It also has slight antihistamine properties and blocks serotonergic properties.
Drug Interactions ::
Zuclopenthixol may enhance the sedative effects of alcohol and the effects of barbiturates and other CNS depressants. Zuclopenthixol reduces the antihypertensive effect of guanethidine. Concomitant use of metoclopramide and piperazine with zuclopenthixol increases the risk of extrapyramidal symptoms. Increased risk of severe neurotoxicity with lithium and sibutramine. Increased anticholinergic side effects with drugs with anticholinergic properties. Potentially Fatal: Antagonises effect of apomorphine, levodopa and other dopamine agonists. Increased risk of blood dyscrasias with clozapine. Increased risk of arrhythmias with dugs that prolong QT interval e.g. class Ia and III antiarrhythmics, erythromycin or cause electrolyte disturbances e.g. thiazide diuretics.
